Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells

Journal of Clinical Oncology

Volumn 33, Issue 14, 2015, Pages 1543-1550

  Stevanović, Sanja ^a   Draper, Lindsey M ^a   Langhan, Michelle M ^a   Campbell, Tracy E ^a   Kwong, Mei Li ^a   Wunderlich, John R ^a   Dudley, Mark E ^a   Yang, James C ^a   Sherry, Richard M ^a   Kammula, Udai S ^a   Restifo, Nicholas P ^a   Rosenberg, Steven A ^a   Hinrichs, Christian S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CD137 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOVITINIB; FLUDARABINE; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IPILIMUMAB; IRINOTECAN; IXABEPILONE; METHYLENE DIMESYLATE; PACLITAXEL; PEMETREXED; TOPOTECAN;

ADOPTIVE T CELL THERAPY; ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLITIS; CYSTITIS; CYTOKINE PRODUCTION; DIARRHEA; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSPOT ASSAY; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 7; HYPOTENSION; HYPOXIA; IMMUNOREACTIVITY; INFECTION; LEUKOPENIA; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; METABOLIC DISORDER; METASTATIC CERVICAL CANCER; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; RADIATION INJURY; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UPREGULATION; URETER OBSTRUCTION; UTERINE CERVIX CANCER; WART VIRUS; ALPHAPAPILLOMAVIRUS; CYTOTOXIC T LYMPHOCYTE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; REMISSION; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS;

EID: 84933508708     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.9093     Document Type: Article

References (38)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
2. Ramondetta L: What is the appropriate approach to treating women with incurable cervical cancer? J Natl Compr Canc Netw 11:348-355, 2013
3. Hinrichs CS, Rosenberg SA: Exploiting the curative potential of adoptive T cell therapy for cancer. Immunol Rev 257:56-71, 2014
4. Hinrichs CS, Restifo NP: Reassessing target antigens for adoptive T cell therapy. Nat Biotechnol 31:999-1008, 2013
5. Bollard CM, Gottschalk S, Torrano V, et al: Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 32:798-808, 2014
6. Heslop HE, Slobod KS, Pule MA, et al: Long-term outcome of EBV-specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925-935, 2010
7. Robbins PF, Morgan RA, Feldman SA, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917-924, 2011
8. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy. Clin Cancer Res 17:4550-4557, 2011
9. Kochenderfer JN, Dudley ME, Feldman SA, et al: B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119:2709-2720, 2012
10. Kochenderfer JN, Wilson WH, Janik JE, et al: Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116:4099-4102, 2010
11. Grupp SA, Kalos M, Barrett D, et al: Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518, 2013
12. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
13. Tran E, Turcotte S, Gros A, et al: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641-645, 2014
14. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003
15. Jin J, Sabatino M, Somerville R, et al: Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35:283-292, 2012
16. Wolfl M, Kuball J, Ho WY, et al: Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110:201-210, 2007
17. Wehler TC, Karg M, Distler E, et al: Rapid identification and sorting of viable virus-reactive CD4+ and CD8+ T cells based on antigen-triggered CD137 expression. J Immunol Methods 339:23-37, 2008
18. Zandvliet ML, van Liempt E, Jedema I, et al: Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother 34:307-319, 2011
19. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al: FOXP3 expression accurately defines the population of intratumoral regulatory T-cells that selectively accumulate in metastatic melanoma lesions. Blood 112:4953-4960, 2008
20. Yao X, Ahmadzadeh M, Lu YC, et al: Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119:5688-5696, 2012
21. Tewari KS, Sill MW, Long HJ 3rd, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734-743, 2014
22. Monk BJ, Mas Lopez L, Zarba JJ, et al: Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562-3569, 2010
23. Santin AD, Sill MW, McMeekin DS, et al: Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 122:495-500, 2011
24. Mackay HJ, Tinker A, Winquist E, et al: A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 116:163-167, 2010
25. Moody CA, Laimins LA: Human papillomavirus oncoproteins: Pathways to transformation. Nat Rev Cancer 10:550-560, 2010
26. Kenter GG, Welters MJP, Valentijn ARPM, et al: Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838-1847, 2009
27. Maciag PC, Radulovic S, Rothman J: The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27:3975-3983, 2009
28. Borysiewicz LK, Fiander A, Nimako M, et al: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527, 1996
29. Steller MA, Gurski KJ, Murakami M, et al: Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4:2103-2109, 1998
30. Ferrara A, Nonn M, Sehr P, et al: Dendritic cell-based tumor vaccine for cervical cancer II: Results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129:521-530, 2003
31. Van Poelgeest MI, Welters MJ, van Esch EM, et al: HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 11:88, 2013
32. Robbins PF, Lu YC, El-Gamil M, et al: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:747-752, 2013
33. Ojesina AI, Lichtenstein L, Freeman SS, et al: Landscape of genomic alterations in cervical carcinomas. Nature 506:371-375, 2014
34. Wright AA, Howitt BE, Myers AP, et al: Oncogenic mutations in cervical cancer: Genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 119:3776-3783, 2013
35. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
36. Von Hoff DD, Green S, Surwit EA, et al: Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer: A Southwest Oncology Group study. Am J Clin Oncol 13:433-435, 1990
37. Sutton GP, Blessing JA, McGuire WP, et al: Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: A Gynecologic Oncology Group study. Am J Obstet Gynecol 168:805-807, 1993
38. Sutton GP, Blessing JA, Photopulos G, et al: Gynecologic Oncology Group experience with ifosfamide. Semin Oncol 17:6-10, 1990